Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

Miscellaneous

This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901).
Miscellaneous
II
Moots, Paul
NCT03962543
VICCNEU1997

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients

Neuro-Oncology

The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred / progressed after radiation and temozolomide chemotherapy.
Neuro-Oncology
III
Moots, Paul
NCT02796261
VICCNEU1670

Study of AG-881 in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Neuro-Oncology

Study AG881-C-004 is a phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy of AG-881 to placebo in participants with residual or recurrent Grade 2 glioma with an IDH1 or IDH2 mutation who have undergone surgery as their only treatment. Participants will be required to have central confirmation of IDH mutation status prior to randomization. Approximately 366 participants are planned to be randomized 1:1 to receive orally administered AG-881 40 mg QD or placebo.
Neuro-Oncology
III
Moots, Paul
NCT04164901
VICCNEU2015

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: